KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) has shared an update.
KYORIN Pharmaceutical Co., Ltd. has entered into a global license agreement with Novartis Pharma AG for the development and commercialization of KRP-M223, an MRGPRX2 antagonist targeting allergic and inflammatory diseases like chronic spontaneous urticaria. This agreement grants Novartis exclusive worldwide rights, while KYORIN retains commercialization rights in Japan. The deal includes an upfront payment of USD 55 million, potential milestone payments up to USD 777.5 million, and tiered royalties, marking a significant step in KYORIN’s global strategy and potentially impacting its financial outlook.
More about KYORIN Pharmaceutical Co.,Ltd.
KYORIN Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development of innovative drugs to address unmet medical needs. The company is committed to creating high-value new drugs under its long-term vision ‘Vision 110’ and aims to contribute to global health through its product development.
YTD Price Performance: -8.97%
Average Trading Volume: 86,864
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen78.5B
Learn more about 4569 stock on TipRanks’ Stock Analysis page.